Three of the 60 volunteers eligible for the COVID-19 vaccine trial have received the first shots. The core purpose of the first phase of human trials is to evaluate the safety of the vaccine when used on humans, not its effectiveness, potency, or ability to provoke an immune response in the body.
About 200 people have registered to participate in the clinical trials of the COVID-19 vaccine Nanocovax. The test will run for 56 days from the date the first injection is given. Participants will be under medical monitoring for six months.
“In the world, there have been very few vaccine trials with unexpected reactions, and we hope Nanocovax vaccine is no exception,” said Prof., Dr. Do Quyet, Director of the Military Medical University.
“To ensure the highest safety for the volunteers, we had to best prepare, even for the life-threatening circumstances,” he said.
“We pledge to assess [the vaccine] objectively, honestly, and transparently, and submit the proposals to the health ministry for later-stage trials,” he continued.
